论文部分内容阅读
目的:观察卡托普利联用倍他乐克治疗扩张型心肌病(DCM)的疗效、安全性并探讨其作用。方法:60例DCM患者随机分为治疗组(30例)和对照组(30例),对照组给予强心、利尿和血管扩张剂常规治疗,治疗组在常规治疗心功能稳定后,在地高辛和利尿剂基础上加用卡托普利和倍他乐克。分别于半年后进行随访。治疗组与对照组患者的心率、血压、左室射血分数(LVEF)及疗效的比较。结果:治疗组与对照组相比,在心率、血压、左室射血分数(LVEF)均有改善(P<0.05)。治疗组有效率90%,对照组有效率66.7%,差异有统计学意义(P<0.05)。治疗组再次入院率13.3%,对照组30%,差异有统计学意义(P<0.05)。结论:卡托普利并倍他乐克治疗DCM有较好疗效。
Objective: To observe the efficacy and safety of captopril in combination with metoprolol in the treatment of dilated cardiomyopathy (DCM). Methods: Sixty patients with DCM were randomly divided into treatment group (30 cases) and control group (30 cases). The control group was treated with cardiotomy, diuretic and vasodilator routinely. After the conventional treatment of cardiac function was stable, Xin and diuretics based on the addition of captopril and Betaloc. After six months were followed up. Comparison of heart rate, blood pressure, left ventricular ejection fraction (LVEF) and therapeutic effect between treatment group and control group. Results: Compared with the control group, the heart rate, blood pressure and left ventricular ejection fraction (LVEF) were improved in the treatment group (P <0.05). The effective rate was 90% in the treatment group and 66.7% in the control group, the difference was statistically significant (P <0.05). Treatment group re-admission rate was 13.3%, 30% in the control group, the difference was statistically significant (P <0.05). Conclusions: Captopril and metoprolol have good efficacy in the treatment of DCM.